SIGA Technologies Inc. - SIGA STOCK NEWS

SIGA Technologies, Inc. (SIGA) has declared a special dividend of $0.45 per share on its common stock. This dividend will be payable on June 2, 2022, to shareholders recorded by the end of business on May 17, 2022. CEO Phil Gomez stated that this decision reflects the company's strong financial performance in 2020 and 2021, along with confidence in future prospects. SIGA specializes in countermeasures for health security, notably its lead product TPOXX, an antiviral for smallpox, with significant orders from the U.S. government amounting to approximately $705 million.

SIGA Technologies, Inc. (SIGA) announced a business update webcast scheduled for May 5, 2022, at 4:30 P.M. ET. The call will feature key executives including CEO Dr. Phil Gomez and CFO Daniel Luckshire. SIGA focuses on health security, with its primary product being TPOXX, an antiviral drug for smallpox, backed by approximately $705 million in U.S. government procurement. The oral formulation of TPOXX received FDA approval in 2018, while the EMA approved it in January 2022. More details are available on SIGA's website.

SIGA Technologies, Inc. (SIGA) reported robust financial results for 2021, achieving $133.7 million in total revenues, an increase from $89.1 million in 2020. The company delivered approximately $113 million of its oral TPOXX® to the U.S. government, amid significant supply chain challenges. International product sales rose to $13 million, compared to $2 million in 2020. SIGA also repurchased 3.8 million shares, representing about 5% of shares outstanding. With EMA approval for oral Tecovirimat in early 2022, SIGA is well-positioned for further growth.

SIGA Technologies, Inc. (SIGA) has initiated a clinical program to expand the FDA label for TPOXX® to include Post-Exposure Prophylaxis (PEP) for smallpox. The first study will compare immune responses to the Jynneos vaccine in participants receiving TPOXX. A second study aims to develop a safety dataset for extending TPOXX's dosing from 14 to 28 days. The research is supported by a $26 million R&D contract with the U.S. Department of Defense, highlighting concerns about smallpox as a potential bioweapon. TPOXX was previously approved for treating smallpox in July 2018.

SIGA Technologies, Inc. (SIGA) will host a webcast and conference call to provide a business update on March 3, 2022, at 4:30 PM ET. Participating will be CEO Dr. Phil Gomez and CFO Daniel Luckshire. The call can be accessed via a dedicated phone line or through a live webcast available on the company’s website. SIGA focuses on the health security market, with its lead product TPOXX® approved for treating human smallpox and various pox diseases. The company highlights the importance of TPOXX in biodefense and preparedness.

SIGA Technologies has announced a collaboration with Bioarchitech to investigate the use of TPOXX® (tecovirimat) combined with Bioarchitech's oncolytic vaccinia immunotherapy platform. This partnership aims to enhance the efficacy of cancer treatments by utilizing TPOXX to allow for higher doses of vaccinia vectors, potentially improving patient outcomes. TPOXX has FDA approval for smallpox treatment and has shown effectiveness against various orthopoxviruses. This collaboration reflects SIGA's commitment to advancing health security through innovative therapies.

SIGA Technologies (SIGA) announced its participation in the Edison Group’s Global Healthcare Open House Conference on January 25-27, 2022. CEO Phil Gomez will present and be available for 1x1 meetings. The company presentation will be available on demand starting January 26 at 7am ET on edison.com. This follows SIGA's recent FDA and EMA approvals for its lead product, TPOXX, an antiviral for smallpox and related diseases. For registration details, visit SIGA's investor page.

SIGA Technologies, Inc. (SIGA) has received European Medicines Agency (EMA) approval for oral tecovirimat, the same formulation previously approved by the U.S. FDA. The approval allows SIGA to market tecovirimat for treating smallpox, monkeypox, cowpox, and vaccinia complications in the EU, Norway, Iceland, and Liechtenstein. This regulatory milestone supports SIGA's commitment to health security and preparedness against biological threats. The company aims to enhance global access to this critical antiviral medication while maintaining its intellectual property rights.

SIGA Technologies, Inc. (SIGA) announced that Health Canada has approved oral TPOXX® (tecovirimat) for treating human smallpox in adults and children over 13 kg. This approval marks a significant milestone, facilitated by support from the Canadian Department of National Defence, ensuring the continued supply for stockpiling as a key countermeasure. SIGA's TPOXX is a vital antiviral drug that was previously FDA-approved in July 2018. The partnership with Meridian Medical Technologies will promote international sales of TPOXX outside the U.S.